What is Riboscience?
Riboscience is at the forefront of pioneering RNA-based therapeutics and precision medicine, aiming to revolutionize patient care by addressing previously untreatable diseases. Their innovative platform is designed to accelerate drug discovery, with a strategic focus on developing treatments for oncology and virology. By employing structure-guided design, Riboscience creates drug candidates that are both safe and effective. A key development is their ENPP1 inhibitor, which is currently undergoing Phase 2 clinical trials. The company's overarching goal is to produce first-in-class and best-in-class treatments that substantially enhance patient outcomes.
How much funding has Riboscience raised?
Riboscience has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Riboscience?
With the recent influx of capital, Riboscience is poised to accelerate its clinical development pipeline, particularly for its oncology and virology programs. The 'large-scale late-stage funding' suggests a focus on scaling operations, advancing its lead ENPP1 inhibitor through Phase 2 trials, and potentially preparing for later-stage regulatory submissions. This strategic investment will likely bolster research and development efforts, expand its scientific team, and support the necessary infrastructure for bringing its RNA-based therapeutics to market. The company's commitment to precision medicine indicates a forward-looking approach to personalized patient care.
See full Riboscience company page
